Third Arc Bio is advancing antibody technology by unlocking the powerful biology of immune synapses to address solid tumors and autoimmune diseases. The company focuses on the development of multifunctional antibodies and next-generation biologics, including T cell engager programs, to treat cancer and inflammatory conditions. Based in the biotech sector, it emphasizes engineering of epitopes and antibody architectures to optimize function and target engagement across oncology and immunology indications.
No recent deals for this company.